Benzinga | May 6, 2021 08:51AM EDT

Fusion Pharmaceuticals Announces Clinical Collaboration With Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA In Patients With Solid Tumors Expressing IGF-1R

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion's lead candidate, [225Ac]-FPI-1434 (FPI-1434), in combination with Merck's anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA(r) (pembrolizumab), in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R).